Biogen (BIIB) Competitors $144.87 +1.19 (+0.83%) Closing price 04:00 PM EasternExtended Trading$145.39 +0.52 (+0.36%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, DNLI, GILD, IONS, MRNA, PRTA, SAVA, VRTX, BMY, and LLYShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Denali Therapeutics Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Cassava Sciences Vertex Pharmaceuticals Bristol Myers Squibb Eli Lilly and Company Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Do analysts prefer AMGN or BIIB? Amgen currently has a consensus target price of $304.43, indicating a potential upside of 10.82%. Biogen has a consensus target price of $181.65, indicating a potential upside of 25.39%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.24Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32 Is AMGN or BIIB more profitable? Amgen has a net margin of 18.96% compared to Biogen's net margin of 15.31%. Amgen's return on equity of 174.71% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% Biogen 15.31%13.85%8.32% Which has stronger valuation and earnings, AMGN or BIIB? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.42$4.09B$12.2322.46Biogen$9.68B2.20$1.63B$10.4613.85 Does the media refer more to AMGN or BIIB? In the previous week, Amgen had 36 more articles in the media than Biogen. MarketBeat recorded 58 mentions for Amgen and 22 mentions for Biogen. Amgen's average media sentiment score of 1.47 beat Biogen's score of 1.37 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 49 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 15 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AMGN or BIIB? Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Do insiders & institutionals believe in AMGN or BIIB? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAmgen beats Biogen on 12 of the 16 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.24B$3.13B$5.73B$10.29BDividend YieldN/A2.36%5.88%4.63%P/E Ratio13.8521.1777.0026.56Price / Sales2.20450.43525.94121.18Price / Cash6.2045.4037.2060.52Price / Book1.269.5413.936.32Net Income$1.63B-$53.02M$3.29B$271.37M7 Day Performance1.58%0.44%0.72%2.19%1 Month Performance4.52%4.00%4.41%6.80%1 Year Performance-26.91%8.57%84.19%27.95% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.6992 of 5 stars$144.87+0.8%$181.65+25.4%-28.0%$21.24B$9.68B13.857,605Positive NewsAMGNAmgen4.6431 of 5 stars$279.37-1.5%$304.43+9.0%-18.5%$150.25B$33.42B22.8228,000Positive NewsDNLIDenali Therapeutics4.2256 of 5 stars$15.55+0.8%$33.62+116.2%-56.3%$2.25B$330.53M-5.51430Positive NewsGILDGilead Sciences4.9417 of 5 stars$115.73+0.6%$115.39-0.3%+33.3%$143.41B$28.75B23.0217,600Positive NewsAnalyst ForecastInsider TradeIONSIonis Pharmaceuticals3.7976 of 5 stars$60.77-0.7%$67.88+11.7%+50.6%$9.69B$705M-33.031,069Insider TradeAnalyst RevisionMRNAModerna4.5278 of 5 stars$24.15-3.9%$42.88+77.6%-64.1%$9.37B$3.24B-3.205,800PRTAProthena3.4303 of 5 stars$8.59+0.5%$19.75+129.9%-62.7%$460.25M$135.16M-1.52130News CoverageAnalyst RevisionSAVACassava Sciences2.6265 of 5 stars$2.15-0.7%$2.00-6.8%-92.6%$103.63MN/A-0.8430Positive NewsVRTXVertex Pharmaceuticals4.9079 of 5 stars$393.95-0.5%$497.10+26.2%-20.0%$101.02B$11.02B28.166,100Positive NewsBMYBristol Myers Squibb4.9044 of 5 stars$46.54-1.3%$56.38+21.1%-7.4%$94.72B$48.30B18.7634,100Positive NewsDividend AnnouncementLLYEli Lilly and Company4.9979 of 5 stars$740.56+1.8%$950.17+28.3%-17.4%$701.55B$45.04B48.4547,000Trending NewsAnalyst Forecast Related Companies and Tools Related Companies Amgen Competitors Denali Therapeutics Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts